Literature DB >> 8983861

Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

R M Hoetelmans1, D M Burger, P L Meenhorst, J H Beijnen.   

Abstract

Zidovudine is the cornerstone of current antiretroviral treatment of human immunodeficiency virus (HIV) infection. Its use, however, frequently leads to adverse reactions, including myelosuppression. Zidovudine pharmacokinetics show large interindividual variation with indications of pharmacokinetic-pharmacodynamic relationships, but a clear therapeutic window has not yet been defined. Individualisation of zidovudine therapy with monitoring of drug concentrations might be desirable. This review considers (intracellular) monitoring of zidovudine and anabolites for individualisation of zidovudine therapy and the achievements in describing pharmacokinetic-pharmacodynamic relationships so far.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8983861     DOI： 10.2165/00003088-199630040-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


  90 in total

1.  Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus.

Authors:  B N Stretcher; A J Pesce; P E Hurtubise; P T Frame
Journal:  Ther Drug Monit       Date:  1992-08       Impact factor: 3.681

2.  Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

Authors:  E Lotterer; M Ruhnke; M Trautmann; R Beyer; F E Bauer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

4.  Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

Authors:  M Ruhnke; F E Bauer; M Seifert; M Trautmann; H Hille; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  Quantitative relationships between zidovudine exposure and efficacy and toxicity.

Authors:  G L Drusano; F M Balis; S R Gitterman; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

6.  Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.

Authors:  P Tosi; P Calabresi; F A Goulette; C A Renaud; J W Darnowski
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

7.  Pharmacokinetics of zidovudine in patients with liver cirrhosis.

Authors:  A M Taburet; S Naveau; G Zorza; J N Colin; J F Delfraissy; J C Chaput; E Singlas
Journal:  Clin Pharmacol Ther       Date:  1990-06       Impact factor: 6.875

8.  Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.

Authors:  T C Meng; M A Fischl; A M Boota; S A Spector; D Bennett; Y Bassiakos; S H Lai; B Wright; D D Richman
Journal:  Ann Intern Med       Date:  1992-01-01       Impact factor: 25.391

9.  The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

Authors:  J Balzarini; R Pauwels; M Baba; P Herdewijn; E de Clercq; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1988-03-01       Impact factor: 5.858

10.  Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast.

Authors:  M J Shelton; A Portmore; M R Blum; B M Sadler; R C Reichman; G D Morse
Journal:  Pharmacotherapy       Date:  1994 Nov-Dec       Impact factor: 4.705
View more
  9 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

3.  Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography.

Authors:  Michele Di Mascio; Sharat Srinivasula; Abesh Bhattacharjee; Lily Cheng; Lucia Martiniova; Peter Herscovitch; Juan Lertora; Dale Kiesewetter
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of zidovudine. An update.

Authors:  E P Acosta; L M Page; C V Fletcher
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

5.  Pharmacokinetic interaction between zidovudine and trimethoprim/sulphamethoxazole in HIV-1 infected children.

Authors:  S Dallas; S E Read; S King; G Koren; R Bendayan
Journal:  Can J Infect Dis       Date:  2000-09

6.  Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.

Authors:  Hervé Trout; France Mentré; Xavière Panhard; Alissi Kodjo; Lélia Escaut; Pascal Pernet; Jean-Gérard Gobert; Daniel Vittecoq; Anne-Laure Knellwolf; Charles Caulin; Jean-François Bergmann
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

7.  Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.

Authors:  Xavière Panhard; Mayeule Legrand; Anne-Marie Taburet; Bertrand Diquet; Cécile Goujard; France Mentré
Journal:  Eur J Clin Pharmacol       Date:  2007-08-11       Impact factor: 2.953

Review 8.  Pharmacokinetic Considerations with the Use of Antiepileptic Drugs in Patients with HIV and Organ Transplants.

Authors:  Jorge J Asconapé
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-09       Impact factor: 5.081

9.  Combination of Colistin and Azidothymidine Demonstrates Synergistic Activity against Colistin-Resistant, Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Ya-Ting Chang; Tsung-Ying Yang; Po-Liang Lu; Shang-Yi Lin; Liang-Chun Wang; Sheng-Fan Wang; Ya-Ju Hsieh; Sung-Pin Tseng
Journal:  Microorganisms       Date:  2020-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.